This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Tyme Technologies, Inc.
6/10/2021
Hello, and welcome to the Time Technologies, Inc. Fiscal Year 2021 Financial Results and Business Update Conference Call. As a brief reminder, all participants are currently in a listen-only mode. If anyone requires operator assistance during the conference, please press star zero on your telephone keypad. Following the presentation, there will be a question and answer session. Note that this conference call is being recorded at the company's request. and will be made available on the company's website following the end of the call. At this time, I'd like to remind our listeners that remarks made during this call may state management intentions, beliefs, expectations, or future projections. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the federal securities laws and are based on times, current expectations, and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from these contemplated by such forward-looking statements are discussed in the periodic report, Time Flies with the Securities and Exchange Commission. These documents are available in the Investors section of the company's website and on the Securities and Exchange Commission's website. We encourage you to review these documents carefully. I would now like to turn the call over to Mr. Richie Cunningham, CEO of Time. Mr. Cunningham, please proceed.
Thank you, operator, and welcome everyone to our presentation this evening. I'm Richie Cunningham, CEO of Time, and it's my pleasure to meet with you to share the findings of our strategic review and the path forward. As you will learn today, every aspect of the company was contemplated. Our pipeline, strategic vision, personnel, clinical process, and data. I would say it was quite a significant undertaking, and it took several months to complete. My prior work experience, which spans across the life cycle of the pharmaceutical business, came in handy throughout the review process. From leading an early drug discovery biotech, with having the understanding and knowing the importance of early translational data, to the launch and commercialization of several drugs throughout my career. Now, with that being said, the clear outlier on this slide is my time in the NFL. I get it. really doesn't apply much to biotech, except for the fact that performing at a high level of success requires focus and discipline. Now, personally, I always had a passion for finding opportunities that could positively impact the lives of people. And working in healthcare offered me a wonderful opportunity to do just that. When looking to transition from the NFL, I was fortunate to meet the CEO of Premier. As many of you know, Premier is one of the largest buying groups for healthcare providers. Mr. O'Leary at the time gave me my first opportunity, and I will always be grateful to him for sharing with me his wealth of experience and knowledge. Now, during that time, I also got a chance to meet with the CEOs from the largest and most successful hospital systems and learned about the delivery of health care. I then followed that same leadership team from Premier to a turnaround opportunity, which was Valiant Pharmaceuticals, now Bosch Health, where I led and built commercial teams in sales and marketing. From there, I was recruited to Beringer Ingelheim, where I had a great run, launching a couple blockbuster drugs in addition to the tyrosine kinase inhibitor by the name of GeoTriff. Now, after my time in a large pharmaceutical organization, I then ventured out to biotech, where I became the CEO of an early stage biotech company. While there, I made two acquisitions in my first two years, including a spin-out from Pfizer by the name of Icogen, and then later acquiring a Sanofi Genzyme R&D unit in rare disease. From those acquisitions, we built an early stage pipeline that led to multiple licensing deals with companies such as Roche, Sanofi, GSK, and others before exiting via a cell of the company. Following the cell of ICOGEN, I became aware of the opportunity at time. After my due diligence, I was very intrigued. Time, I believe, was a great fit. The SM88's novel approach towards helping people without sacrifice, coupled with the initial data, in my view, was and is compelling. I've been here now for about six months, and I can share with you that my level of excitement for time and our future has only increased. As you all know, a company is only as good as the people that comprise it. That was top of mind when I came on board. I'm fortunate to have the support of an accomplished team of individuals who have done it before in other organizations and know how to apply their experience towards making time a success. Those of you who know time, may be more familiar with the team on the left side of this slide. We have our founder, Chairman and Chief Scientific Officer Steve Hoffman, our Chief Business Officer, Dr. Jonathan Eckerd, and James Bill, our Chief Legal Officer. I also need to recognize the team who are not on this slide. Note that we have a very strong, committed, and competent group that make up this company. I'm proud to be part of it. I also want to take a minute to introduce the two recent team additions that we're pleased to have on board. and will greatly benefit from the wealth of experience they each bring to us in their given fields. At this time, I'll turn it over to Dr. Van Turno and then Frank Profito to introduce themselves. Jan?
Thank you. Good afternoon, good evening. My name is Dr. Jan Van Turno. I'm a pediatric hematologist, oncologist, and genetic epidemiologist. I'm licensed as a physician both in the U.S. and Europe. I started my career as an attending at Children's Hospital LA, University of Southern California, and as a physician scientist with an NIH-funded research program in genetic epi and neural network in pediatric cancer. Following my academic work, I joined Amgen as a safety officer in oncology and was part of a team that successfully filed an NDA for Kip Evans. Subsequently, I joined Bristol-Myers Squibb in their late-stage development program and was part of the team that successfully filed the satinib in CML. Subsequently, I moved into the early-stage drug development as senior director at BMS, where I led several IND submissions of their pre-IND assets, as well as leading the team that brought elotuzumab, a monoclonal antibody against CS1, into BMS, I led the early development phase of the compound that was later successfully approved in multiple myeloma. I then joined Astellas Pharma as executive director, where I led the development of an anti-IGFR-IR, a dual mTOR inhibitor, and a FAC inhibitor. Subsequently, I moved to Inovio as VP clinical development for oncology, where I led several INDs and developed their DNA vaccine program in oncology. After Inovio, I joined Natera, a senior VP and head of oncology, to develop their cell-free DNA technique that they had optimized in the pre-neonatal space and apply it to oncology with the use of liquid biopsies in pre- and post-treatment diagnosis in oncology. I subsequently worked as a consultant, and I recently joined Time after having been introduced by Richard Cunningham and After having seen the very impressive first-in-human data and other elements in the pipeline, I accepted the position as acting CMO. I'm very thrilled to join Time at this time in their development, and I've been impressed by the experience of the management team as well as the opportunities that lay ahead of us to meet the unmet medical needs in patients with the assets that time has. I'm now going to pass the mic to Frank Porfido, Chief Financial Officer.
You're reading a preview of the TYME Q4 2021 earnings call.
Free account.